Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBeacon: ALN-6400 in VWD and HMB
NCT07575308Phase 2Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
A Phase 2 trial of ALN-6400 in von Willebrand disease (VWD), Heavy menstrual bleeding, sponsored by Alnylam Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
ALN-6400
03
Conditions
von Willebrand disease (VWD)Heavy menstrual bleeding
Beyond the preview
Go deeper on NCT07575308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575308.